Sage Journals: Discover world-class research

Abstract

Drug delivery systems (DDS) are designed to improve the pharmacological and therapeutic effect. In the past few decades, there are some problems that impeded applications of particulate DDS have been resolved, with several DDS formulations of anticancer now approved for clinical use. Liposomal nanoparticles (LNs) encapsulating therapeutic agents have been recognized as one of the most advanced classes of DDS. Liposomal nanoparticles (LNs) could encapsulate both conventional anticancer drugs and the new genetic drugs with several properties such as high drug-to-lipid ratio, excellent retention of drug and a long circulation lifetime. These excellent properties of LNs have the potentials to offer new treatments in area of cancer therapy. Here, we will discuss recent advances in this field involving conventional anticancer drugs as well as the new genetic drugs.

Keywords

Drug delivery systems Liposomal nanoparticles Cancer therapy Genetic drugs Targeting.

References

Allen

T. M.

Cullis

P. R.

Drug delivery systems: Entering the mainstream. Science 303, 1818–1822 (2004). DOI: 10.1126/science.1095833 [PMid: 15031496].

Samad

Sultana

Aqil

Liposomal drug delivery systems: An update review. Curr Drug Deliv 4, 297–305 (2007). DOI: 10.2174/156720107782151269 [PMid: 17979650].

Mamot

Drummond

D. C.

Hong

Kirpotin

D. B.

Park

J. W.

Liposome-based approaches to overcome anticancer drug resistance. Drug Resist Updat 6, 271–279 (2003). DOI: 10.1016/S1368–7646(03)00082–7.

Dass

C. R.

Liposome-mediated delivery of oligodeoxynucleotides

in vivo. Drug Deliv 9, 169–180 (2002). DOI: 10.1080/15227950290097606 [PMid: 12396734].

Venkatraman

S. S.

L. L.

Natarajan

J. V.

Chattopadhyay

Polymer- and liposome-based nanoparticles in targeted drug delivery. Front Biosci (Schol Ed), 2 801–814 (2010). DOI: 10.2741/S103.

Medina

O. P.

Zhu

Kairemo

Targeted liposomal drug delivery in cancer. Curr Pharm Des 10, 2981–2989 (2004). DOI: 10.2174/1381612043383467 [PMid: 15379663].

Langner

Kral

T. E.

Liposome-based drug delivery systems. Pol J Pharmacol 51, 211–222 (1999). [PMid: 10600035].

Margalit

Liposome-mediated drug targeting in topical and regional therapies. Crit Rev Ther Drug Carrier Syst 12, 233–261 (1995). DOI: 10.1615/CritRevTherDrugCarrierSyst.v12.i2–3.30 [PMid:9501970].

Yanagihara

Kaneda

Inui

Okada

Liposome-mediated gene transfer. Mol Cell Biol Hum Dis Ser 5, 64–82 (1995). [PMid:9532561].

10.

Bangham

A. D.

Standish

M. M.

Watkins

J. C.

Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 13, 238–252 (1965). DOI: 10.1016/S0022–2836(65)80093–6.

11.

Gabizon

A. A.

Liposomal drug carrier systems in cancer chemotherapy: Current status and future prospects. J Drug Target 10, 535–538 (2002). DOI: 10.1080/1061186021000043061 [PMid: 12683720].

12.

Ranson

Howell

Cheeseman

Margison

Liposomal drug delivery. Cancer Treat Rev 22, 365–379 (1996). DOI: 10.1016/S0305–7372(96)90009–2.

13.

Fielding

R. M.

Liposomal drug delivery. Advantages and limitations from a clinical pharmacokinetic and therapeutic perspective. Clin Pharmacokinet 21, 155–164 (1991). DOI: 10.2165/00003088–199121030–00001 [PMid: 1764868].

14.

Allen

T. M.

Liposomal drug formulations. Rationale for development and what we can expect for the future. Drugs 56, 747–756 (1998). DOI: 10.2165/00003495–199856050–00001 [PMid:9829150].

15.

Xiang

T. X.

Anderson

B. D.

Liposomal drug transport: A molecular perspective from molecular dynamics simulations in lipid bilayers. Adv Drug Deliv Rev 58, 1357–1378 (2006). DOI: 10.1016/j.addr.2006.09.002 [PMid: 17092601].

16.

Nounou

M. I.

El-Khordagui

L. K.

Khalafallah

N. A.

Khalil

S. A.

Liposomal formulation for dermal and transdermal drug delivery: Past, present and future. Recent Pat Drug Deliv Formul 2, 9–18 (2008). DOI: 10.2174/187221108783331375.

17.

Bally

Bailey

Sugihara

Grieshaber

Voros

Stadler

Liposome and lipid bilayer arrays towards biosensing applications. Small 6, 2481–2497 (2010). DOI: 10.1002/smll.201000644 [PMid:20925039].

18.

Fenske

D. B.

Cullis

P. R.

Liposomal nanomedicines. Expert Opin Drug Deliv 5, 25–44 (2008). DOI: 10.1517/17425247.5.1.25 [PMid: 18095927].

19.

Chonn

Cullis

P. R.

Recent advances in liposomal drug-delivery systems. Curr Opin Biotechnol 6, 698–708 (1995). DOI: 10.1016/0958–1669(95)80115–4.

20.

Lila

A. S. Abu

Ishida

Kiwada

Recent advances in tumor vasculature targeting using liposomal drug delivery systems. Expert Opin Drug Deliv 6, 1297–1309 (2009). DOI: 10.1517/17425240903289928 [PMid: 19780711].

21.

Chandran

Roy

Mishra

Recent trends in drug delivery systems: Liposomal drug delivery system-preparation and characterisation. Indian J Exp Biol 35, 801–809 (1997). [PMid:9475051].

22.

Toonen

P. A.

Crommelin

D. J.

Immunoglobulins as targeting agents for liposome encapsulated drugs. Pharm Weekbl Sci 5, 269–280 (1983). DOI: 10.1007/BF02074854 [PMid:6364035].

23.

Korting

H. C.

Blecher

Schafer-Korting

Wendel

Topical liposome drugs to come: What the patent literature tells us. A review. J Am Acad Dermatol 25, 1068–1071 (1991). DOI: 10.1016/0190–9622(91)70309-P.

24.

Przybylo

Borowik

Langner

Application of liposome based sensors in high-throughput screening systems. Comb Chem High Throughput Screen 10, 441–450 (2007). DOI: 10.2174/138620707781996439.

25.

Kozubek

Gubernator

Przeworska

Stasiuk

Liposomal drug delivery, a novel approach: PLARosomes. Acta Biochim Pol 47, 639–649 (2000). [PMid: 11310966].

26.

Webb

M. S.

Rebstein

Lamson

Bally

M. B.

Liposomal drug delivery: Recent patents and emerging opportunities. Recent Pat Drug Deliv Formul 1, 185–194 (2007). DOI: 10.2174/187221107782331593.

27.

Park

J. W.

Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 4, 95–99 (2002). DOI: 10.1186/bcr432 [PMid: 12052251] [PMCid: 138729].

28.

Wiebe

V. J.

DeGregorio

M. W.

Liposome-encapsulated amphotericin B: A promising new treatment for disseminated fungal infections. Rev Infect Dis 10, 1097–1101 (1988). DOI: 10.1093/clinids/10.6.1097.

29.

Desormeaux

Bergeron

M. G.

Targeting HIV with liposomeencapsulated antivirals. Zentralbl Bakteriol 282, 225–231 (1995). DOI: 10.1016/S0934–8840(11)80121–0.

30.

Meyerhoff

U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 28, 42–48; discussion 49–51 (1999). DOI: 10.1086/515085 [PMid: 10028069].

31.

Beyer

C. F.

Zhang

Hernandez

Vitale

Nguyen

Ayral-Kaloustian

Gibbons

J. J.

The microtubule-active antitumor compound TTI-237 has both paclitaxel-like and vincristinelike properties. Cancer Chemother Pharmacol 64, 681–689 (2009). DOI: 10.1007/s00280–008–0916–2 [PMid: 19132373].

32.

Ong

Liem

N. L.

Schmid

M. A.

Verrills

N. M.

Papa

R. A.

Marshall

G. M.

Mackenzie

K. L.

Kavallaris

Lock

R. B.

A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts. J Pharmacol Exp Ther 324, 434–442 (2008). DOI: 10.1124/jpet.107.128926 [PMid: 17986648].

33.

Novichkova

E. A.

Onishchenko

G. E.

Shtil

A. A.

Microtubule depolymerization by vincristine causes cell death after transition from C mitosis to interphase. Dokl Biol Sci 393, 575–578 (2003). DOI: 10.1023/B:DOBS.0000010328.92771.95 [PMid: 14994555].

34.

Tanner

K. D.

Levine

J. D.

Topp

K. S.

Microtubule disorientation and axonal swelling in unmyelinated sensory axons during vincristine-induced painful neuropathy in rat. J Comp Neurol 395, 481–492 (1998). DOI: 10.1002/(SICI)1096–9861(19980615)395:4<481::AID-CNE5>3.3.CO;2-T: DOI: 10.1002/(SICI)1096–9861(19980615)395:4 <481::AID-CNE5>3.0.CO;2-Y.

35.

Hirose

Takiguchi

Mcrotubule changes in hematologic malignant cells treated with paclitaxel and comparison with vincristine cytotoxicity. Blood Cells Mol Dis 21, 119–130 (1995). DOI: 10.1006/bcmd.1995.0014 [PMid:8846041].

36.

Boman

N. L.

Masin

Mayer

L. D.

Cullis

P. R.

Bally

M. B.

Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res 54, 2830–2833 (1994). [PMid:8187061].

37.

Semple

P. L.

Webb

M. K.

de Villiers

J. C.

Laws

E. R.

Jr.

Pituitary apoplexy. Neurosurgery 56, 65–72; discussion 72–63 (2005).

38.

Park

J. W.

Benz

C. C.

Martin

F. J.

Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol 31, 196–205 (2004). DOI: 10.1053/j.seminoncol.2004.08.009 [PMid:15717745].

39.

Hoffmann

Troch

Eidherr

Traub-Weidinger

Jonak

Muellauer

Raderer

90Y-ibritumomab tiuxetan (Zevalin) in heavily pretreated patients with mucosa associated lymphoid tissue lymphoma. Leuk Lymphoma 52, 42–45 (2011). DOI: 10.3109/10428194.2010.534519.

40.

Beaven

A. W.

Shea

T. C.

Moore

D. T.

Feldman

Ivanova

Ferraro

Ford

Smith

Goy

A phase I study evaluating ibritumomab tiuxetan (Zevalin(R)) in combination with bortezomib (Velcade(R)) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma. Leuk Lymphoma 53, 254–258 (2011). DOI: 10.3109/10428194.2011.608445.

41.

Bruneau

J. C.

O'Marcaigh

Smith

O. P.

Gemtuzumab ozogamicin (Mylotarg) upregulates tissue factor expression but not secretion of inflammatory cytokines TNF-alpha or IL-8. Leuk Res 34, 1232–1234 (2010). DOI: 10.1016/j.leukres.2010.04.008 [PMid:20471678].

42.

Esmaeli

McLaughlin

Pro

Samaniego

Gayed

Hagemeister

Romaguera

Cabanillas

Neelapu

S. S.

Banay

Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of earlystage extranodal indolent ocular adnexal lymphoma. Ann Oncol 20, 709–714 (2009). DOI: 10.1093/annonc/mdn692 [PMid: 19150940].

43.

Otte

Diagnostic imaging prior to 90Y-ibritumomab tiuxetan (Zevalin) treatment in follicular non-Hodgkin's lymphoma. Hell J Nucl Med 11, 12–15 (2008). [PMid: 18392220].

44.

Duvic

Talpur

Optimizing denileukin diftitox (Ontak) therapy. Future Oncol 4, 457–469 (2008). DOI: 10.2217/14796694.4.4.457 [PMid: 18684057].

45.

Dai

L. C.

Midkine translocated to nucleoli and involved in carcinogenesis. World J Gastroenterol 15, 412–416 (2009). DOI: 10.3748/wjg.15.412 [PMid: 19152444] [PMCid: 2653361].

46.

Presumey

Duroux-Richard

Courties

Apparailly

Cationic liposome formulations for RNAi-based validation of therapeutic targets in rheumatoid arthritis. Curr Opin Mol Ther 12, 325–330 (2010). [PMid:20521221].

47.

Johnson

E. L.

Singh

Johnson-Holiday

C. M.

Grizzle

W. E.

Partridge

E. E.

Lillard

J. W.

Jr. Singh

CCR9 interactions support ovarian cancer cell survival and resistance to cisplatin-induced apoptosis in a PI3K-dependent and FAK-independent fashion. J Ovarian Res 17, 3:15 (2010).

48.

Aponte

Jiang

Lakkis

M. J.

Edwards

Albitar

Vitonis

Mok

S. C.

Cramer

D.W.

Activation of platelet-activating factor receptor and pleiotropic effects on tyrosine phospho-EGFR/Src/FAK/paxillin in ovarian cancer. Cancer Res 68, 5839–5848 (2008). DOI: 10.1158/0008–5472.CAN-07–5771 [PMid: 18632638] [PMCid: 2586603].

49.

Golubovskaya

V. M.

Zheng

Zhang

J. L.

Cance

W. G.

The direct effect of focal adhesion kinase (FAK), dominant-negative FAK, FAK-CD and FAK siRNA on gene expression and human MCF-7 breast cancer cell tumorigenesis. BMC Cancer 9, 280 (2009). DOI: 10.1186/1471–2407–9–280 [PMid: 19671193] [PMCid: 3087335].

50.

H. Y.

Qian

A. R.

Shang

Kong

L. M.

Bian

H. J.

Chen

Z. N.

siRNA targeted against HAb18 G/CD147 inhibits MMP-2 secretion, actin and FAK expression in hepatocellular carcinoma cell line via ERK1/2 pathway. Cancer Lett 247, 336–344 (2007). DOI: 10.1016/j.canlet.2006.05.017 [PMid: 16815629].

51.

Dai

Jiang

Tan

G.C.

Chen

Torbenson

Leong

K. W.

Mao

H. Q.

Chitosan-DNA nanoparticles delivered by intrabiliary infusion enhance liver-targeted gene delivery. Int J Nanomedicine 1, 507–522 (2006). DOI: 10.2147/nano.2006.1.4.507 [PMid: 17369870] [PMCid: 1828073].

52.

Dai

L. C.

Wang

Yao

Y. L.

Ping

J. L.

J. F.

Antisense oligonucleotide targeting midkine suppresses in vivo angiogenesis. World J Gastroenterol 13, 1208–1213 (2007). [PMid: 17451201].

53.

Dai

L. C.

Wang

Yao

Min

L. S.

Ping

J. L.

J. F.

Antisense oligonucleotides targeting midkine inhibit tumor growth in an in situ human hepatocellular carcinoma model. Acta Pharmacol Sin 28, 453–458 (2007). DOI: 10.1111/j.1745–7254.2007.00532.x [PMid: 17303011].

54.

Herringson

T. P.

Patlolla

R. R.

Altin

J. G.

Targeting of plasmid DNA-lipoplexes to cells with molecules anchored via a metal chelator lipid. J Gene Med 11, 1048–1063 (2009). DOI: 10.1002/jgm.1394 [PMid: 19757485].

55.

Wilson

Zhou

Champion

H. C.

Alber

Tang

Z. L.

Kennel

Watkins

Huang

Pitt

: Targeted delivery of oligodeoxynucleotides to mouse lung endothelial cells in vitro and in vivo. Mol Ther 12, 510–518 (2005). DOI: 10.1016/j.ymthe.2005.04.005 [PMid: 15953766].

56.

Zhou

Yuan

Wilson

Yang

Mokotoff

Pitt

Efficient intracellular delivery of oligonucleotides formulated in folate receptor-targeted lipid vesicles. Bioconjug Chem 13, 1220–1225 (2002). DOI: 10.1021/bc025569z [PMid: 12440856].

57.

Semple

S. C.

Klimuk

S. K.

Harasym

T. O.

Dos Santos

Ansell

S. M.

Wong

K. F.

Maurer

Stark

Cullis

P. R.

Hope

M. J.

Scherrer

Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: Formation of novel small multilamellar vesicle structures. Biochim Biophys Acta 1510, 152–166 (2001). DOI: 10.1016/S0005–2736(00)00343–6.

58.

Kaneda

[Liposome-mediated gene delivery]. Tanpakushitsu Kakusan Koso 42, 1806–1813 (1997). [PMid:9279116].

59.

Maruyama

[PEG-liposome in DDS and clinical studies]. Nippon Rinsho 56, 632–637 (1998). [PMid:9549348].

60.

Chanan-Khan

A. A.

Lee

Pegylated liposomal doxorubicin and immunomodulatory drug combinations in multiple myeloma: Rationale and clinical experience. Clin Lymphoma Myeloma 7 (Suppl 4), S163–169 (2007). DOI: 10.3816/CLM.2007.s.018.

61.

Clarenc

J. P.

Degols

Leonetti

J. P.

Milhaud

Lebleu

Delivery of antisense oligonucleotides by poly(L-lysine) conjugation and liposome encapsulation. Anticancer Drug Des 8, 81–94 (1993). [PMid:8476504].

62.

Ikehara

Kojima

Development of a novel oligomannose-coated liposome-based anticancer drug-delivery system for intraperitoneal cancer. Curr Opin Mol Ther 9, 53–61 (2007). [PMid: 17330402].

63.

Madani

Peralvarez-Marin

Graslund

Liposome Model Systems to Study the Endosomal Escape of Cell-Penetrating Peptides: Transport across Phospholipid Membranes Induced by a Proton Gradient. J Drug Deliv 2011, 897592 (2011). DOI: 10.1155/2011/897592 [PMid:21490758] [PMCid: 3065815].

64.

Taneichi

Tanaka

Kakiuchi

Uchida

Liposome-coupled peptides induce long-lived memory CD8 T cells without CD4 T cells. PLoS One 5, e15091 (2010). DOI: 10.1371/journal.pone.0015091 [PMid:21264321] [PMCid: 3020143].

65.

Kim

S. T.

Lee

K. M.

Park

H. J.

Jin

S. E.

Ahn

W. S.

Kim

C. K.

Topical delivery of interleukin-13 antisense oligonucleotides with cationic elastic liposome for the treatment of atopic dermatitis. J Gene Med 11, 26–37 (2009). DOI: 10.1002/jgm.1268 [PMid: 19006098].

66.

Chen

Xiang

Zeng

Inhibition of PCNA antisense oligonucleotides mediated by liposome on mRNA expression and proliferation of h-RPE cells. J Huazhong Univ Sci Technolog Med Sci 26, 392–395 (2006). DOI: 10.1007/s11596–006–0402–1 [PMid: 17120729].

67.

Tarhini

A. A.

Belani

C. P.

Luketich

J. D.

Argiris

Ramalingam

S. S.

Gooding

Pennathur

Petro

Kane

Liggitt

A phase I study of concurrent chemotherapy (paclitaxel and carboplatin) and thoracic radiotherapy with swallowed manganese superoxide dismutase plasmid liposome protection in patients with locally advanced stage III non-small-cell lung cancer. Hum Gene Ther 22, 336–342 (2011). DOI: 10.1089/hum.2010.078 [PMid:20873987] [PMCid: 3057216].

68.

Epperly

M. W.

Wang

Jones

J. A.

Dixon

Montesinos

C. A.

Greenberger

J. S.

Antioxidant-chemoprevention diet ameliorates late effects of total-body irradiation and supplements radioprotection by MnSOD-plasmid liposome administration. Radiat Res 175, 759–765 (2011). DOI: 10.1667/RR2398.1 [PMid:21466381] [PMCid: 3119545].

69.

Epperly

M. W.

Smith

Zhang

Goff

J. P.

Franicola

Greenberger

Komanduri

Wang

Greenberger

J. S.

Modulation of in utero total body irradiation induced newborn mouse growth retardation by maternal manganese superoxide dismutase-plasmid liposome (MnSOD-PL) gene therapy. Gene Ther 18, 579–583 (2011). DOI: 10.1038/gt.2010.178 [PMid: 21248791] [PMCid: 3111807].

70.

Maurer

Fenske

D. B.

Cullis

P. R.

Developments in liposomal drug delivery systems. Expert Opin Biol Ther 1, 923–947 (2001). DOI: 10.1517/14712598.1.6.923 [PMid: 11728226].

71.

Oku

Tokudome

Asai

Tsukada

Evaluation of drug targeting strategies and liposomal trafficking. Curr Pharm Des 6, 1669–1691 (2000). DOI: 10.2174/1381612003398816 [PMid: 10974160].

72.

Goyal

Kumar

S. G. Vijaya

Singh

Katare

O. P.

Mishra

D. N.

Liposomal drug delivery systems–clinical applications. Acta Pharm 55, 1–25 (2005). [PMid: 15907221].

73.

Tashjian

J. A.

Dewhirst

M. W.

Needham

Viglianti

B. L.

Rationale for and measurement of liposomal drug delivery with hyperthermia using non-invasive imaging techniques. Int J Hyperthermia 24, 79–90 (2008). DOI: 10.1080/02656730701840147 [PMid: 18214771] [PMCid: 2755546].

Targeting Liposomal Nanomedicine to Cancer Therapy

Abstract

Keywords

References